



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2017





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2017 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

February 2017

N = 7131



Health Authority	Male	Female	All
FRASER	1366	386	1752
INTERIOR	373	99	472
NORTHERN	133	82	215
VANCOUVER COASTAL	3362	453	3815
VANCOUVER ISLAND	691	149	840
	<b>5925</b>	<b>1169</b>	<b>7094</b>
		<b>Unknown/not stated:</b>	<b>37</b>
		<b>Total:</b>	<b>7131</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2012 - February 2017)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2012 - February 2017)








1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (February 2012 - February 2017)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (February 2012 - February 2017)






### 1.6 Percent Distribution of Active Participants by CD4 Count (February 2012 - February 2017)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(February 2012 - February 2017)






### 1.8 Active and Inactive Participants (February 2012 - February 2017)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2012 - February 2017)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (February 2012 - February 2017)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(February 2012 - February 2017)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (February 2012 - February 2017)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2012 - February 2017)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (February 2012 - February 2017)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(February 2012 - February 2017)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2012 - February 2017)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(February 2012 - February 2017)






1.18 Baseline CD4 for Antiretroviral First Starts  
(February 2012 - February 2017)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(February 2012 - February 2017)**








### 1.20 Cumulative Resistance Testing Results by Resistance Category (February 2012 - February 2017)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2012 - February 2017)





## 2.1 Duration of ARV treatment in the Province of BC, 1987-2017 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	25	5	0	5	5	760	5	<40	3
1988	25	7	0	7	7	610	7	<40	3
1989	24	56	2	58	51	510	56	<40	3
1990	23	62	1	63	58	500	61	<40	3
1991	23	38	3	41	33	570	40	<40	3
1992	23	70	6	76	61	570	72	<40	3
1993	22	145	16	161	143	560	155	<40	3
1994	20	93	13	106	95	570	100	<40	3
1995	20	115	24	139	117	570	134	<40	3
1996	18	360	58	418	358	600	403	<40	3
1997	16	291	39	330	299	620	322	<40	3
1998	15	207	43	250	210	575	232	<40	3
1999	16	176	40	216	187	550	205	<40	3
2000	16	135	36	171	150	515	162	<40	3
2001	15	131	34	165	140	615	154	<40	3
2002	14	138	28	166	145	540	161	<40	3
2003	13	171	34	205	177	590	195	<40	3
2004	12	174	39	213	186	610	206	<40	3
2005	11	200	49	249	211	620	237	<40	3
2006	10	202	44	246	204	570	232	<40	3
2007	9	273	55	328	277	590	305	<40	3
2008	8	308	70	378	320	618	357	<40	3
2009	8	338	76	414	346	620	393	<40	3
2010	7	300	69	369	310	630	348	<40	3
2011	6	364	71	435	376	670	413	<40	3
2012	5	294	60	354	303	670	338	<40	3
2013	4	279	70	349	287	640	322	<40	3
2014	3	298	57	355	295	700	333	<40	3
2015	2	336	54	390	340	650	370	<40	3
2016	1	321	68	389	356	590	385	<40	3
2017	0	54	11	65	60	525	63	577	3
<b>Total:</b>		<b>5941</b>	<b>1170</b>	<b>7111</b>					

### Definitions:

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	6970	737	2262	<40	2021	590
FEB-2016	6989	735	2064	<40	1865	590
MAR-2016	6995	737	2155	<40	1956	590
APR-2016	7014	734	2053	<40	1863	580
MAY-2016	7043	747	2071	<40	1883	590
JUN-2016	7062	739	2179	<40	1990	610
JUL-2016	7052	751	1949	<40	1760	600
AUG-2016	7069	751	2068	<40	1876	590
SEP-2016	7108	752	2214	<40	1994	600
OCT-2016	7138	747	2153	<40	1929	600
NOV-2016	7169	743	2110	<40	1879	580
DEC-2016	7193	752	1872	<40	1681	620
JAN-2017	7183	749	2325	<40	1986	590
FEB-2017	7131	756	1912	<40	1635	600

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	1516	2280	116	<40	104	465
FEB-2016	1508	2325	83	353	74	380
MAR-2016	1515	2311	87	130	83	440
APR-2016	1519	2294	87	<50	74	360
MAY-2016	1504	2376	79	<40	69	350
JUN-2016	1515	2361	72	76	56	505
JUL-2016	1539	2315	81	<50	74	455
AUG-2016	1563	2223	94	158	78	360
SEP-2016	1550	2281	96	240	80	360
OCT-2016	1524	2450	74	<40	70	415
NOV-2016	1522	2490	73	1007	57	360
DEC-2016	1522	2521	52	122	43	480
JAN-2017	1538	2500	88	140	76	417
FEB-2017	1599	2249	80	964	67	440

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2016	6940	1516	9	16	152	168	-12	12409
FEB-2016	6960	1508	5	18	178	163	20	12437
MAR-2016	6968	1515	9	24	170	173	8	12471
APR-2016	6988	1519	6	20	166	157	20	12505
MAY-2016	7018	1504	7	23	159	143	30	12536
JUN-2016	7032	1515	12	34	163	167	14	12579
JUL-2016	7015	1539	11	25	136	157	-17	12611
AUG-2016	7031	1563	10	40	165	172	16	12671
SEP-2016	7073	1550	5	27	179	151	42	12714
OCT-2016	7102	1524	11	22	161	138	29	12745
NOV-2016	7128	1522	20	27	181	160	26	12791
DEC-2016	7152	1522	11	26	153	141	24	12831
JAN-2017	7150	1538	19	22	140	144	-2	12863
FEB-2017	7111	1599	8	24	137	191	-39	12897

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2016	58	6405	446	61	<b>6970</b>	0.83%	91.89%	6.40%	0.88%	<b>100.00%</b>
FEB-2016	59	6436	435	59	<b>6989</b>	0.84%	92.09%	6.22%	0.84%	<b>100.00%</b>
MAR-2016	54	6442	438	61	<b>6995</b>	0.77%	92.09%	6.26%	0.87%	<b>100.00%</b>
APR-2016	54	6464	439	57	<b>7014</b>	0.77%	92.16%	6.26%	0.81%	<b>100.00%</b>
MAY-2016	57	6495	437	54	<b>7043</b>	0.81%	92.22%	6.20%	0.77%	<b>100.00%</b>
JUN-2016	60	6499	447	56	<b>7062</b>	0.85%	92.03%	6.33%	0.79%	<b>100.00%</b>
JUL-2016	57	6496	442	57	<b>7052</b>	0.81%	92.12%	6.27%	0.81%	<b>100.00%</b>
AUG-2016	57	6509	447	56	<b>7069</b>	0.81%	92.08%	6.32%	0.79%	<b>100.00%</b>
SEP-2016	58	6546	447	57	<b>7108</b>	0.82%	92.09%	6.29%	0.80%	<b>100.00%</b>
OCT-2016	58	6578	445	57	<b>7138</b>	0.81%	92.15%	6.23%	0.80%	<b>100.00%</b>
NOV-2016	61	6603	446	59	<b>7169</b>	0.85%	92.10%	6.22%	0.82%	<b>100.00%</b>
DEC-2016	62	6636	437	58	<b>7193</b>	0.86%	92.26%	6.08%	0.81%	<b>100.00%</b>
JAN-2017	61	6616	443	63	<b>7183</b>	0.85%	92.11%	6.17%	0.88%	<b>100.00%</b>
FEB-2017	60	6577	439	55	<b>7131</b>	0.84%	92.23%	6.16%	0.77%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	4 19%	2818 42%	4 19%	2485 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	17 81%	4165 62%
FEB-2016	10 36%	2851 42%	9 32%	2519 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	18 64%	4135 61%
MAR-2016	9 26%	2877 43%	7 21%	2542 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	26 76%	4112 61%
APR-2016	12 35%	2893 43%	9 26%	2567 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	5 0%	22 65%	4103 60%
MAY-2016	8 26%	2894 43%	8 26%	2578 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	0 0%	6 0%	23 74%	4120 61%
JUN-2016	11 26%	2924 43%	11 26%	2602 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	1 2%	9 0%	31 72%	4117 60%
JUL-2016	9 28%	2903 43%	9 28%	2583 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	0 0%	9 0%	23 72%	4113 60%
AUG-2016	11 19%	2936 43%	11 19%	2626 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	6 10%	22 0%	42 71%	4097 60%
SEP-2016	14 33%	2969 43%	12 28%	2659 39%	0 0%	81 1%	0 0%	8 0%	0 0%	6 0%	3 7%	25 0%	27 63%	4102 60%
OCT-2016	11 35%	2996 43%	11 35%	2688 39%	0 0%	82 1%	0 0%	9 0%	0 0%	7 0%	0 0%	26 0%	20 65%	4098 59%
NOV-2016	17 37%	3023 44%	17 37%	2722 39%	0 0%	78 1%	0 0%	7 0%	0 0%	6 0%	0 0%	35 1%	29 63%	4088 59%
DEC-2016	7 18%	3059 44%	7 18%	2754 40%	0 0%	77 1%	0 0%	6 0%	0 0%	6 0%	0 0%	35 1%	33 83%	4077 59%
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4052 58%
FEB-2017	12 35%	3071 44%	10 29%	2782 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2016	17	81%	3848	57%
FEB-2016	18	64%	3828	57%
MAR-2016	25	74%	3809	56%
APR-2016	22	65%	3812	56%
MAY-2016	23	74%	3834	56%
JUN-2016	32	74%	3829	56%
JUL-2016	23	72%	3830	56%
AUG-2016	48	81%	3831	56%
SEP-2016	29	67%	3847	56%
OCT-2016	20	65%	3848	56%
NOV-2016	29	63%	3852	56%
DEC-2016	33	83%	3843	55%
JAN-2017	19	59%	3829	55%
FEB-2017	22	65%	3771	55%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1128 34%	1 9%	326 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1155 35%	1 8%	317 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1171 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1197 37%	0 0%	293 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1728 53%	10 83%	1220 38%	0 0%	282 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1709 53%	12 80%	1235 38%	0 0%	283 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	3 21%	1689 53%	11 79%	1242 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1663 52%	26 90%	1254 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1643 52%	9 82%	1269 40%	1 9%	262 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%
OCT-2016	0 0%	8 0%	2 18%	1615 51%	9 82%	1263 40%	0 0%	261 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
NOV-2016	0 0%	9 0%	3 16%	1588 51%	15 79%	1282 41%	1 5%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
DEC-2016	0 0%	9 0%	3 17%	1588 50%	15 83%	1305 41%	0 0%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
JAN-2017	0 0%	9 0%	2 14%	1557 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1516 49%	12 75%	1305 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%
OCT-2016	0	0%	1	0%
NOV-2016	0	0%	1	0%
DEC-2016	0	0%	1	0%
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	996 41%	0 0%	307 13%	1 25%	854 35%	1 25%	257 11%
APR-2016	3 33%	990 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	969 41%	1 25%	299 13%	2 50%	836 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	295 13%	0 0%	830 35%	2 29%	262 11%
SEP-2016	2 50%	949 41%	0 0%	295 13%	0 0%	819 35%	2 50%	265 11%
OCT-2016	1 20%	944 41%	2 40%	300 13%	1 20%	814 35%	1 20%	269 12%
NOV-2016	7 88%	936 41%	1 13%	294 13%	0 0%	812 35%	0 0%	269 12%
DEC-2016	7 70%	927 40%	0 0%	290 13%	0 0%	806 35%	3 30%	273 12%
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	800 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	279 12%	0 0%	792 35%	1 20%	266 12%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	6 55%	1020 44%	4 36%	458 20%	0 0%	66 3%	1 9%	821 35%	0 0%	1 0%
FEB-2016	7 64%	1062 45%	4 36%	468 20%	0 0%	60 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1115 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1153 47%	4 22%	491 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1182 47%	4 24%	493 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1216 48%	9 35%	506 20%	0 0%	58 2%	1 4%	788 31%	0 0%	1 0%
JUL-2016	14 70%	1251 49%	5 25%	517 20%	0 0%	57 2%	1 5%	784 30%	0 0%	1 0%
AUG-2016	20 59%	1305 49%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1364 50%	10 33%	545 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%
OCT-2016	15 94%	1411 51%	1 6%	561 20%	0 0%	53 2%	0 0%	777 28%	0 0%	1 0%
NOV-2016	18 72%	1452 52%	5 20%	580 21%	0 0%	53 2%	2 8%	756 27%	0 0%	1 0%
DEC-2016	9 75%	1479 52%	2 17%	587 21%	0 0%	53 2%	1 8%	762 27%	0 0%	1 0%
JAN-2017	13 81%	1518 53%	3 19%	588 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1559 54%	4 22%	589 20%	0 0%	48 2%	0 0%	730 25%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2016	2285	32.78	1944	27.89	1609	23.08	158	2.27	61	0.88	913	13.10
FEB-2016	2279	32.61	1925	27.54	1668	23.87	153	2.19	59	0.84	905	12.95
MAR-2016	2266	32.39	1903	27.21	1706	24.39	154	2.20	61	0.87	905	12.94
APR-2016	2244	31.99	1894	27.00	1757	25.05	154	2.20	57	0.81	908	12.95
MAY-2016	2256	32.03	1887	26.79	1781	25.29	157	2.23	54	0.77	908	12.89
JUN-2016	2255	31.93	1877	26.58	1811	25.64	152	2.15	56	0.79	911	12.90
JUL-2016	2225	31.55	1865	26.45	1847	26.19	150	2.13	57	0.81	908	12.88
AUG-2016	2210	31.26	1839	26.01	1913	27.06	142	2.01	56	0.79	909	12.86
SEP-2016	2191	30.82	1831	25.76	1977	27.81	144	2.03	57	0.80	908	12.77
OCT-2016	2169	30.39	1829	25.62	2033	28.48	146	2.05	57	0.80	904	12.66
NOV-2016	2174	30.33	1817	25.35	2074	28.93	143	1.99	59	0.82	902	12.58
DEC-2016	2181	30.32	1809	25.15	2102	29.22	143	1.99	58	0.81	900	12.51
JAN-2017	2154	29.99	1794	24.98	2136	29.74	139	1.94	63	0.88	897	12.49
FEB-2017	2124	29.79	1773	24.86	2165	30.36	133	1.87	55	0.77	881	12.35

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	24	4	3	4	8	5	365
APR-2016	20	2	1	2	2	9	580
MAY-2016	23	2	1	3	4	13	510
JUN-2016	34	5	5	6	10	8	380
JUL-2016	25	2	6	6	3	7	320
AUG-2016	40	2	7	6	12	13	410
SEP-2016	27	8	2	6	4	4	253
OCT-2016	22	2	2	6	6	5	370
NOV-2016	27	3	4	5	7	8	390
DEC-2016	26	4	2	5	3	11	400
JAN-2017	22	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2016	11049	3054
FEB-2016	11142	3135
MAR-2016	11202	3183
APR-2016	11248	3216
MAY-2016	11308	3265
JUN-2016	11364	3296
JUL-2016	11407	3331
AUG-2016	11452	3337
SEP-2016	11479	3341
OCT-2016	11510	3365
NOV-2016	11553	3386
DEC-2016	11585	3399
JAN-2017	11609	3421
FEB-2017	11640	3432

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month









3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
February 2017

N = 7131

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2017

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2017

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2017

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2017

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2017

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>35</b>	<b>48</b>	<b>23</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>71</b>	<b>93</b>	<b>51</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>345</b>	<b>452</b>	<b>266</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	37
	50+	*	*	81
<b>Total HSDA:</b>	<b>175</b>	<b>232</b>	<b>132</b>	
<b>Total HA:</b>		<b>626</b>	<b>825</b>	<b>472</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	61	62	*
	35-49	173	197	*
	50+	386	560	*
<b>Total HA:</b>		<b>626</b>	<b>825</b>	<b>472</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	490	656	373
Female	136	169	99

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	472	53	600	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	5	*
	<5 years	12	*
	<b>Total HSDA:</b>	<b>35</b>	<b>23</b>
KOOTENAY BOUNDARY	10 years or more	38	26
	5 years or more	19	15
	<5 years	14	10
	<b>Total HSDA:</b>	<b>71</b>	<b>51</b>
OKANAGAN	10 years or more	182	128
	5 years or more	77	62
	<5 years	86	76
	<b>Total HSDA:</b>	<b>345</b>	<b>266</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	87	58
	5 years or more	44	38
	<5 years	44	36
	<b>Total HSDA:</b>	<b>175</b>	<b>132</b>
<b>Total HA:</b>		<b>626</b>	<b>472</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	325	223
5 years or more	145	118
<5 years	156	131
<b>Total HA:</b>	<b>626</b>	<b>472</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	36	53	13	23
KOOTENAY BOUNDARY	63	112	23	40
OKANAGAN	197	696	62	255
THOMPSON/CARIBOO/SHUSWAP	127	441	36	112
<b>Total:</b>	<b>423</b>	<b>1302</b>	<b>134</b>	<b>430</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>99</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	5	5	*
	20-34	23	24	*
	35-49	110	121	*
	50+	188	253	*
	<b>Total HSDA:</b>		<b>326</b>	<b>403</b>
FRASER NORTH	0-19	17	17	5
	20-34	110	111	85
	35-49	350	394	262
	50+	494	773	403
	<b>Total HSDA:</b>		<b>971</b>	<b>1295</b>
FRASER SOUTH	0-19	10	10	6
	20-34	100	102	72
	35-49	375	429	302
	50+	451	664	368
	<b>Total HSDA:</b>		<b>936</b>	<b>1205</b>
<b>Total HA:</b>		<b>2233</b>	<b>2903</b>	<b>1752</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	32	32	15
	20-34	233	237	176
	35-49	835	944	643
	50+	1133	1690	918
<b>Total HA:</b>		<b>2233</b>	<b>2903</b>	<b>1752</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1693	2231	1366
Female	540	672	386

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1752	50	602	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	162	111
	5 years or more	98	86
	<5 years	66	52
	<b>Total HSDA:</b>	<b>326</b>	<b>249</b>
FRASER NORTH	10 years or more	469	343
	5 years or more	249	197
	<5 years	253	215
	<b>Total HSDA:</b>	<b>971</b>	<b>755</b>
FRASER SOUTH	10 years or more	438	343
	5 years or more	253	204
	<5 years	245	201
	<b>Total HSDA:</b>	<b>936</b>	<b>748</b>
<b>Total HA:</b>		<b>2233</b>	<b>1752</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1069	797
	5 years or more	600	487
	<5 years	564	468
<b>Total HA:</b>		<b>2233</b>	<b>1752</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	129	417	41	80
FRASER NORTH	235	1454	59	258
FRASER SOUTH	203	1213	45	344
<b>Total:</b>	<b>567</b>	<b>3084</b>	<b>145</b>	<b>682</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	180
FRASER NORTH	638
FRASER SOUTH	517
<b>Total:</b>	<b>1335</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	23
	35-49	*	*	69
	50+	*	*	185
	<b>Total HSDA:</b>		<b>326</b>	<b>465</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>159</b>	<b>205</b>
VANCOUVER	0-19	49	52	7
	20-34	438	447	331
	35-49	1502	1729	1104
	50+	2542	4250	1966
	<b>Total HSDA:</b>	<b>4531</b>	<b>6478</b>	<b>3408</b>
<b>Total HA:</b>		<b>5016</b>	<b>7148</b>	<b>3815</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	55	58	9
	20-34	488	498	372
	35-49	1634	1878	1211
	50+	2839	4714	2223
<b>Total HA:</b>		<b>5016</b>	<b>7148</b>	<b>3815</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4405	6278	3362
Female	609	868	453

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3815	52	620	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	168	136
	5 years or more	69	60
	<5 years	89	81
	<b>Total HSDA:</b>	<b>326</b>	<b>277</b>
RICHMOND	10 years or more	75	55
	5 years or more	40	35
	<5 years	44	40
	<b>Total HSDA:</b>	<b>159</b>	<b>130</b>
VANCOUVER	10 years or more	2361	1685
	5 years or more	1219	940
	<5 years	951	783
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4531</b>	<b>3408</b>
<b>Total HA:</b>	<b>5016</b>	<b>3815</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2604	1876
	5 years or more	1328	1035
	<5 years	1084	904
	Never on ART	0	0
<b>Total HA:</b>		<b>5016</b>	<b>3815</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	148	383	58	101
RICHMOND	42	270	14	97
VANCOUVER	553	10142	213	5332
<b>Total:</b>	<b>743</b>	<b>10795</b>	<b>285</b>	<b>5530</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>99</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>290</b>	<b>407</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>111</b>	<b>148</b>
SOUTH VANCOUVER ISLAND	0-19	5	5	*
	20-34	56	58	*
	35-49	204	240	*
	50+	415	644	*
	<b>Total HSDA:</b>		<b>680</b>	<b>947</b>
<b>Total HA:</b>		<b>1081</b>	<b>1502</b>	<b>840</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	5
	20-34	94	99	67
	35-49	327	377	255
	50+	651	1017	513
<b>Total HA:</b>		<b>1081</b>	<b>1502</b>	<b>840</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	876	1219	691
Female	205	283	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	840	53	490	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)







**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	138	110
	5 years or more	66	52
	<5 years	86	66
	<b>Total HSDA:</b>	<b>290</b>	<b>228</b>
NORTH VANCOUVER ISLAND	10 years or more	51	42
	5 years or more	31	25
	<5 years	29	24
	<b>Total HSDA:</b>	<b>111</b>	<b>91</b>
SOUTH VANCOUVER ISLAND	10 years or more	351	243
	5 years or more	167	138
	<5 years	162	140
	<b>Total HSDA:</b>	<b>680</b>	<b>521</b>
<b>Total HA:</b>		<b>1081</b>	<b>840</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	540	395
	5 years or more	264	215
	<5 years	277	230
<b>Total HA:</b>		<b>1081</b>	<b>840</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	178	780	85	220
NORTH VANCOUVER ISLAND	123	244	43	71
SOUTH VANCOUVER ISLAND	189	1590	45	536
<b>Total:</b>	<b>490</b>	<b>2614</b>	<b>173</b>	<b>827</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	39
NORTH VANCOUVER ISLAND	32
SOUTH VANCOUVER ISLAND	92
<b>Total:</b>	<b>163</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>41</b>	<b>49</b>
NORTH WEST	0-19	*	*	0
	20-34	*	*	8
	35-49	*	*	19
	50+	*	*	22
	<b>Total HSDA:</b>		<b>69</b>	<b>102</b>
NORTHERN INTERIOR	0-19	7	7	*
	20-34	22	24	*
	35-49	76	93	*
	50+	80	130	*
	<b>Total HSDA:</b>		<b>185</b>	<b>254</b>
<b>Total HA:</b>		<b>295</b>	<b>405</b>	<b>215</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	35	41	*
	35-49	116	148	*
	50+	135	207	*
<b>Total HA:</b>		<b>295</b>	<b>405</b>	<b>215</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	181	252	133
Female	114	153	82

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	215	47	540	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	14	6
	5 years or more	17	10
	<5 years	10	8
	<b>Total HSDA:</b>	<b>41</b>	<b>24</b>
NORTH WEST	10 years or more	18	8
	5 years or more	34	28
	<5 years	17	13
	<b>Total HSDA:</b>	<b>69</b>	<b>49</b>
NORTHERN INTERIOR	10 years or more	59	34
	5 years or more	62	56
	<5 years	64	52
	<b>Total HSDA:</b>	<b>185</b>	<b>142</b>
<b>Total HA:</b>		<b>295</b>	<b>215</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	91	48
	5 years or more	113	94
	<5 years	91	73
<b>Total HA:</b>		<b>295</b>	<b>215</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	33	59	7	11
NORTH WEST	66	148	22	30
NORTHERN INTERIOR	102	409	19	184
<b>Total:</b>	<b>201</b>	<b>616</b>	<b>48</b>	<b>225</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	5
NORTH WEST	13
NORTHERN INTERIOR	20
<b>Total:</b>	<b>38</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	31	*
	THOMPSON/CARIBOO/SHUSWAP	*	40	*
	<b>Total HA:</b>	<b>50</b>	<b>88</b>	<b>38</b>
FRASER	FRASER EAST	31	39	25
	FRASER NORTH	52	83	38
	FRASER SOUTH	79	108	59
	<b>Total HA:</b>	<b>162</b>	<b>230</b>	<b>122</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	46	22
	RICHMOND	9	14	8
	VANCOUVER	502	803	409
	<b>Total HA:</b>	<b>536</b>	<b>863</b>	<b>439</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	52	78	38
	NORTH VANCOUVER ISLAND	13	22	11
	SOUTH VANCOUVER ISLAND	34	72	29
	<b>Total HA:</b>	<b>99</b>	<b>172</b>	<b>78</b>
NORTHERN	NORTH EAST	8	10	5
	NORTH WEST	34	58	28
	NORTHERN INTERIOR	66	99	55
	<b>Total HA:</b>	<b>108</b>	<b>167</b>	<b>88</b>
<b>Total:</b>		<b>955</b>	<b>1520</b>	<b>765</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	590	967	466
Female	365	553	299

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	765	50	480	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicstat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.







**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

